50 likes | 248 Views
CTC report. Bronwen Shaw – chair bshaw@doctors.org.uk Andy Peniket – secretary Andy.Peniket@ouh.nhs.uk. CTC operations. Meet 3/year: next meeting 14 th November BSH House New processes working well
E N D
CTC report Bronwen Shaw – chair bshaw@doctors.org.uk Andy Peniket – secretary Andy.Peniket@ouh.nhs.uk
CTC operations • Meet 3/year: next meeting 14th November BSH House • New processes working well • Each meeting preceded in am by ‘PI’ meeting for specific studies (PI plus office staff). Many PIs have taken advantage of this • Regular teleconferences – review progress of each study, invite specific PIs • Letter of understanding for PIs
CTC activity: manuscripts • Published • GvL in ALL (Medd et al) • outcomes in severe autoimmune disease (Snowden et al) • results of RIC allos for mantle cell lymphoma (Cook et al) • a comparison of ATG vs Alemtuzumab based conditioning in aplastic anaemia (Marsh et al) • Preparation/submitted • second allogeneic transplants (Lown et al) • impact of KIR on AML transplant outcomes (Schellekens et al) • pulmonary function post allograft (brown et al) • BEAM-campath for lymphoproliferative disorders (Fox et al) • refractory myeloma (Cook et al) • impact of pre-transplant campath in CLL (Protheroe et al) • Allo SCT in elderly patients (Nikolousis/Craddock et al) • Cord blood retrospective analysis (Snowden/Rocha et al) – joint study with Eurocord • Analysis: Impact of HLA matching on survival (Shaw et al)
CTC activity: supporting ongoing prospective studies • The FIGARO study for high risk AML has just opened (Craddock) • Myeloma X (Cook) • National cord blood studies (Hough) and immune reconstitution • Hodgkin’s study (Peggs) • MCL study (Rule) • Haplo-identical transplant protocols (Raj/Mackinnon/Pagliuca) • Prospective data collection studies • co-morbidities (Gilleece) • intracranial haemorrhage (Stanworth)
CTC activity: new proposals • In development • mesenchymal stromal cells (Dazzi) • invariant NKT cells (Karadimitris) • Myelofibrosis trial (Mead/Gilleece) • New projects: • paediatric refractory AML (O’Hare) • incidence and risks or TTP (Hill) • second line treatments for acute GvHD (Das Gupta) • Surveys: • Late effects (Snowden) • EBV monitoring (Hamblin)